Dyne Therapeutics (DYN) Interest & Investment Income (2019 - 2026)
Dyne Therapeutics (DYN) posted quarterly Interest & Investment Income of $7.8 million for Q2 2026, up 17.55% year-over-year from $6.6 million in Q2 2025, and up 1372.55% quarter-over-quarter from -$612000.0 in Q1 2026.
Powered by 
Analysis
Dyne Therapeutics (DYN) Interest & Investment Income (2019 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Interest & Investment Income for 8 consecutive years, with $7.8 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Interest & Investment Income rose 17.55% year-over-year to $7.8 million; the TTM figure through Jun 2026 stood at $23.3 million (down 1.77% YoY), while the FY2025 annual figure was $29.9 million, up 10.91% from the prior year.
- Interest & Investment Income rose to $7.8 million in Q2 2026 per DYN's latest filing, from -$612000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $9.3 million in Q3 2024 and bottomed at -$661000.0 in Q1 2022.
- Historically, Interest & Investment Income has averaged $2.9 million across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2022 — Interest & Investment Income tumbled 1512.2% — and 2025, when it soared 6234.26%.
- Dyne Therapeutics' Interest & Investment Income stood at $1.3 million in 2022, then surged by 30.48% to $1.8 million in 2023, then jumped by 333.58% to $7.6 million in 2024, then grew by 0.86% to $7.7 million in 2025, then gained by 1.71% to $7.8 million in 2026.
- Business Quant data shows DYN's Interest & Investment Income at $7.8 million in Q2 2026, -$612000.0 in Q1 2026, and $7.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 10.98 Mn |
| 10 | Dyne Therapeutics | 4.01 Bn | 4.01 Bn | - | 7.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7.79 Mn |
| Mar 31, 2026 | -612,000.00 |
| Dec 31, 2025 | 7.66 Mn |
| Sep 30, 2025 | 8.48 Mn |
| Jun 30, 2025 | 6.63 Mn |
| Mar 31, 2025 | 235,000.00 |
| Dec 31, 2024 | 7.59 Mn |
| Sep 30, 2024 | 9.28 Mn |
| Jun 30, 2024 | -108,000.00 |
| Mar 31, 2024 | -132,000.00 |
| Dec 31, 2023 | 1.75 Mn |
| Sep 30, 2023 | 2.19 Mn |
| Jun 30, 2023 | 147,000.00 |
| Mar 31, 2023 | 368,000.00 |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 903,000.00 |
| Jun 30, 2022 | -226,000.00 |
| Mar 31, 2022 | -661,000.00 |
| Dec 31, 2021 | 182,000.00 |
| Sep 30, 2021 | 184,000.00 |